Skip to content
drillr.ai
Sign up

300676.SZ

华大基因

SZSE · Healthcare · M 科研服务 · CN

CNY 41.90
−0.71%
Ask drillr

  • Aug 24, 2026, 11:55 UTC

    BGI Genomics hosted a research visit by 8 institutions on August 24, 2026, with executives including director Zhao Lijian and general manager Hou Yong.

    Source:

  • Aug 21, 2026, 15:34 UTC

    BGI Genomics launched the Huayi series of intelligent terminals based on its self-developed GeneT large model, and introduced the SIRO high-throughput gene sequencing localized medical solution.

    Source:

  • Aug 21, 2026, 10:58 UTC

    BGI Genomics announced its 2026 half-year results, with net profit attributable to shareholders of 47.4046 million yuan, up 718.24% year-on-year.

    Source:

  • Aug 19, 2026, 08:43 UTC

    BGI Genomics' controlling shareholder Shenzhen BGI Tech Solutions Co., Ltd. released a pledge on 7.6 million shares and re-pledged 6.9 million shares to China Merchants Bank Shenzhen Branch on August 18, 2026, for its own production and operation funding needs.

    Source:

  • Aug 6, 2026, 09:34 UTC

    BGI completed its third share buyback on August 5, 2026, repurchasing a total of 6,731,602 shares, representing 1.6092% of total share capital, for a total payment of 251 million yuan.

    Source:

  • Aug 3, 2026, 09:30 UTC

    BGI Genomics announced that as of July 31, 2026, it had repurchased 4.6201 million shares, representing 1.1045% of total share capital, for a total payment of 167 million yuan, and plans to continue executing the buyback program.

    Source:

  • Jul 24, 2026, 11:16 UTC

    BGI Genomics announced that its third-phase share buyback program has reached 1.0208% of total shares, spending 154 million yuan.

    Source:

  • Jul 14, 2026, 08:28 UTC

    BGI Genomics Co., Ltd. conducted its first share repurchase on July 13, 2026, buying back 1.5 million shares (0.3586% of total equity) for a total of RMB 54.2558 million.

    Source: